secwatch.observer — SEC 8-K summary
======================================

Issuer:     CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK:        0001369568
Form:       8-K
Filed at:   2024-07-26T23:59:59+00:00
Accession:  0001193125-24-186261
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Catalyst grants Kye exclusive Canadian rights to AGAMREE for DMD
----------------------------------------------------------------

- Kye Pharmaceuticals gets exclusive Canadian rights to commercialize AGAMREE (vamorolone) for Duchenne Muscular Dystrophy.
- Catalyst will supply product; Kye responsible for Health Canada approval and all commercialization in Canada.
- Catalyst receives upfront payment, plus potential reimbursement, sales milestones, and royalties from Kye.
- Kye already markets Catalyst's FIRDAPSE in Canada; AGAMREE application to Health Canada expected by early 2025.
- Agreement expands AGAMREE's North American footprint beyond U.S. approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1369568/000119312524186261/0001193125-24-186261-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1369568/000119312524186261/d810788d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-186261

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer